NCT03862131: PROactive Evaluation of Function to Avoid CardioToxicity

NCT03862131
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated unstable brain metastasis
https://ClinicalTrials.gov/show/NCT03862131

Comments are closed.

Up ↑